Literature DB >> 35963630

Management of Dyslipidemia in Endocrine Diseases.

Lisa R Tannock1.   

Abstract

Most endocrine disorders are chronic in nature, and thus even a minor effect to increase risk for cardiovascular disease can lead to a significant impact over prolonged duration. Although robust therapies exist for many endocrine disorders (eg suppression of excess hormone amounts, or replacement of hormone deficiencies), the therapies do not perfectly restore normal physiology. Thus, individuals with endocrine disorders are at potential increased cardiovascular disease risk, and maximizing strategies to reduce that risk are needed. This article reviews various endocrine conditions that can impact lipid levels and/or cardiovascular disease risk. Published by Elsevier Inc.

Entities:  

Keywords:  Cardiovascular; Dyslipidemia; Endocrine; Lipids

Mesh：

Substances：

Year:  2022        PMID： 35963630      PMCID： PMC9382690          DOI： 10.1016/j.ecl.2022.02.003

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.748


  90 in total

Review 1.  Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review.

Authors:  I Velho; T M Fighera; P K Ziegelmann; P M Spritzer
Journal:  Andrology       Date:  2017-07-14       Impact factor: 3.842

2.  Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins.

Authors:  J A Beentjes; A van Tol; W J Sluiter; R P Dullaart
Journal:  Atherosclerosis       Date:  2000-12       Impact factor: 5.162

3.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

Review 4.  Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis.

Authors:  A Pizzocaro; W Vena; R Condorelli; A Radicioni; G Rastrelli; D Pasquali; R Selice; A Ferlin; C Foresta; E A Jannini; M Maggi; A Lenzi; R Pivonello; A M Isidori; A Garolla; S Francavilla; G Corona
Journal:  J Endocrinol Invest       Date:  2020-06-21       Impact factor: 4.256

5.  Use of oral corticosteroids and the risk of acute myocardial infarction.

Authors:  Cristina Varas-Lorenzo; Luis Alberto Garcia Rodriguez; Andrew Maguire; Jordi Castellsague; Susana Perez-Gutthann
Journal:  Atherosclerosis       Date:  2006-06-19       Impact factor: 5.162

Review 6.  Testosterone therapy for transgender men.

Authors:  Michael S Irwig
Journal:  Lancet Diabetes Endocrinol       Date:  2016-04-12       Impact factor: 32.069

7.  Subclinical hypothyroidism is associated with coronary artery disease in older persons.

Authors:  Min Min Mya; Wilbert S Aronow
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-10       Impact factor: 6.053

8.  Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials.

Authors:  Patrick Maison; Simon Griffin; Marc Nicoue-Beglah; Nabila Haddad; Beverley Balkau; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

9.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

Review 10.  Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis.

Authors:  Taulant Muka; Clare Oliver-Williams; Setor Kunutsor; Joop S E Laven; Bart C J M Fauser; Rajiv Chowdhury; Maryam Kavousi; Oscar H Franco
Journal:  JAMA Cardiol       Date:  2016-10-01       Impact factor: 14.676
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.